Tamoxifen
tamoxifen citrate — tablets and oral solution (formerly Nolvadex, Soltamox)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Metastatic breast cancer (ER-positive) | Adults (females and males) | Systemic endocrine therapy | FDA Approved |
| Adjuvant treatment of early-stage ER-positive breast cancer | Adults (females and males) | Adjuvant endocrine therapy | FDA Approved |
| DCIS — reduce risk of invasive breast cancer (after surgery and radiation) | Adult women | Risk reduction | FDA Approved |
| Reduction of breast cancer incidence in high-risk women (Gail model 5-year risk ≥1.67%) | Adult women ≥35 years | Chemoprevention | FDA Approved |
Tamoxifen is the most extensively studied SERM in oncology and remains a cornerstone of endocrine therapy for ER-positive breast cancer, particularly in premenopausal women for whom aromatase inhibitors are not appropriate as monotherapy. The EBCTCG 1998 overview of 55 randomised trials (36,689 women) demonstrated that approximately 5 years of tamoxifen reduced annual breast cancer recurrence by 47% and mortality by 26% in ER-positive disease. The ATLAS trial subsequently showed that 10 years of adjuvant tamoxifen further reduced breast cancer recurrence and mortality compared to 5 years, and ASCO guidelines now recommend 5–10 years of adjuvant therapy depending on risk profile. Tamoxifen is also the only agent approved for male breast cancer.
Ovulation induction in anovulatory infertility — Used as an alternative to clomifene citrate. Doses of 20–40 mg daily for 5 days in the early follicular phase. Evidence quality: Moderate (RCTs)
Gynaecomastia (treatment and prevention) — 10–20 mg daily; used in males receiving androgen deprivation therapy or anabolic steroids. Evidence quality: Moderate
Desmoid tumours (aggressive fibromatosis) — 20–40 mg daily as part of multimodal management. Evidence quality: Low (case series)
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Adjuvant therapy — early-stage ER+ breast cancer | 20 mg daily | 20 mg daily for 5–10 years | 20 mg/day | Doses >20 mg/day offer no additional benefit (EBCTCG overview). ASCO recommends 5–10 years based on risk profile. ATLAS trial supports 10-year duration in higher-risk patients |
| Metastatic breast cancer — ER-positive | 20 mg daily | 20–40 mg daily | 40 mg/day | Doses >20 mg/day should be divided BID (morning and evening). Continue until disease progression. Tumour flare may occur in first weeks — does not indicate failure |
| DCIS — risk reduction of invasive cancer | 20 mg daily | 20 mg daily for 5 years | 20 mg/day | After breast surgery and radiation. Discuss boxed-warning risks vs benefits with patient. NSABP B-24: reduced invasive cancer RR 0.57 |
| Chemoprevention — high-risk women | 20 mg daily | 20 mg daily for 5 years | 20 mg/day | Gail model 5-year risk ≥1.67% required. NSABP P-1: 49% reduction in invasive breast cancer. No impact on overall mortality. Consider raloxifene (STAR trial) as alternative in postmenopausal women |
For premenopausal women, tamoxifen remains the standard adjuvant endocrine agent; ASCO and NCCN guidelines support 5–10 years of tamoxifen monotherapy or sequential therapy (tamoxifen followed by an aromatase inhibitor after menopause). Postmenopausal women are typically transitioned to an aromatase inhibitor after 2–3 years of tamoxifen or started directly on an aromatase inhibitor. Tamoxifen can be taken with or without food. Verify pregnancy status before initiation and ensure effective non-hormonal contraception throughout treatment and for 9 months after the last dose (per 2018 FDA PI update).
Pharmacology
Mechanism of Action
Tamoxifen is a non-steroidal selective estrogen receptor modulator that exerts tissue-specific agonist and antagonist effects. In breast tissue, tamoxifen acts as an estrogen antagonist by competitively binding to estrogen receptors (ERs), blocking the binding of oestradiol and inhibiting the transcription of oestrogen-responsive genes that drive tumour cell proliferation. In bone, the cardiovascular system, and the uterus, tamoxifen acts as a partial ER agonist — conferring a protective effect on bone mineral density in postmenopausal women while simultaneously exerting a pro-estrogenic effect on the endometrium, which underlies the increased risk of endometrial hyperplasia and malignancy. Tamoxifen is a prodrug: its primary anti-tumour activity is mediated by its active metabolites endoxifen and 4-hydroxytamoxifen, which have 30- to 100-fold greater affinity for the ER than the parent compound. Metabolic activation depends critically on CYP2D6.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Well absorbed orally; Tmax ~5 h; Cmax ~40 ng/mL (range 35–45) after single 20 mg dose | Can be taken with or without food; steady state reached in 4–8 weeks |
| Distribution | Protein binding >99% (albumin); Css ~122 ng/mL tamoxifen, ~353 ng/mL N-desmethyl tamoxifen (20 mg QD x 3 months) | Highly protein-bound with large Vd; tissue concentrations (especially uterus, breast) exceed plasma levels |
| Metabolism | Hepatic: CYP3A4 (N-demethylation), CYP2D6 (4-hydroxylation to endoxifen). Active metabolites: endoxifen, 4-OH-tamoxifen | CYP2D6 poor metabolisers have lower endoxifen levels — clinical significance debated but avoid strong CYP2D6 inhibitors |
| Elimination | t½ ~5–7 days (tamoxifen), ~14 days (N-desmethyl tamoxifen); ~65% excreted in faeces over 2 weeks as polar conjugates; <30% unchanged drug | Very long t½ means effects persist for weeks after discontinuation; use non-hormonal contraception for 9 months after last dose (2018 FDA PI) |
Side Effects
Adverse effect data are drawn from multiple large clinical trials including NSABP B-14 (adjuvant), NSABP P-1 (chemoprevention, N=13,388), NSABP B-24 (DCIS), and the EBCTCG meta-analysis. The side-effect profile reflects tamoxifen’s dual agonist/antagonist properties: anti-estrogenic effects in breast (therapeutic) and estrogenic effects in endometrium, bone, liver, and the coagulation system (adverse).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hot flashes / vasomotor symptoms | 33–64% | Most common AE; 33% in premenopausal metastatic trials (FDA PI Table 1); up to 64% across studies. Usually improves after 12 months. |
| Vaginal discharge | ~30% | Due to estrogenic effect on vaginal epithelium; 30% vs 15% placebo. Non-purulent; evaluate if bloody or malodorous. |
| Menstrual irregularity / amenorrhoea | 13–25% | Amenorrhoea 16%; altered menses 13% (FDA PI Table 1). More common in premenopausal women. Usually reversible after stopping. |
| Fluid retention / peripheral oedema | ~32% | ~32% vs 30% placebo (NSABP P-1). Typically mild; assess for DVT if asymmetric leg swelling. |
| Vaginal dryness | ~35% | Anti-estrogenic effect on vaginal epithelium; non-hormonal moisturisers recommended. Rate from cross-sectional survey data; may be lower in controlled trials. |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 5–10% | Typically mild; 5% in premenopausal metastatic trial (FDA PI Table 1). Usually self-limiting. |
| Vaginal bleeding | 2–5% | Any new vaginal bleeding warrants prompt gynaecological evaluation to exclude endometrial pathology. |
| Weight gain | ~6% | Reported in cross-sectional studies; multifactorial. |
| Mood changes / depression | 2–6% | Depression 2% (FDA PI Table 1). Also mood swings, irritability; screen at follow-up visits. |
| Fatigue | 4% | 4% in premenopausal metastatic trial (FDA PI Table 1); multifactorial in cancer patients. |
| Bone pain / musculoskeletal pain | 3–6% | Bone pain 6% (FDA PI Table 1). Tumour flare with bone pain may occur in first weeks of therapy. |
| Headache / dizziness / lightheadedness | 2–4% | Generally self-limiting; assess concurrent medications. |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Endometrial adenocarcinoma | 2.20 per 1,000 women-years vs 0.71 placebo (NSABP P-1) | Months to years; risk increases with duration ≥2 years | Annual gynaecological exam. Promptly evaluate any abnormal vaginal bleeding. Routine endometrial sampling in asymptomatic women is NOT recommended (FDA PI). |
| Uterine sarcoma | 0.17 per 1,000 women-years vs 0.04 placebo | Usually long-term users (≥2 years); often higher stage | Report abnormal bleeding. Uterine sarcoma carries poor prognosis; high index of suspicion in long-term users. |
| Pulmonary embolism | 0.75 per 1,000 women-years vs 0.25 placebo; RR 3.01 (NSABP P-1) | 2–60 months (average 27 months); 87% in women ≥50 years | Discontinue tamoxifen immediately. Standard PE management. Three fatal cases in NSABP P-1 tamoxifen arm. |
| Deep vein thrombosis | ~0.8% vs 0.2% placebo; RR 1.59 (NSABP P-1) | 2–57 months (average 19 months) | Discontinue tamoxifen. Anticoagulate per VTE guidelines. Contraindicated for DCIS/risk reduction if history of DVT/PE. |
| Stroke | 1.43 per 1,000 women-years vs 1.00 placebo; RR 1.42 (NSABP P-1) | 1–63 months (average 30 months); 88% in women ≥50 years | Standard stroke management. Four fatal strokes in tamoxifen arm of NSABP P-1. |
| Cataracts / cataract surgery | RR 1.13 for cataracts; RR 1.62 for cataract surgery (NSABP P-1) | Months to years | Baseline and periodic ophthalmological assessment. Advise patients to report visual disturbances promptly. |
| Hepatotoxicity (fatty liver, cholestasis, hepatitis, necrosis) | Rare; some fatalities reported | Variable | Monitor LFTs periodically. Discontinue if significant liver injury. Positive rechallenge/dechallenge reported. |
In patients with metastatic breast cancer (particularly bone metastases), tamoxifen may cause an initial worsening of symptoms (“tumour flare”) within the first weeks of treatment, including increased bone pain, hypercalcaemia, and transient increase in lesion size. This does not indicate treatment failure and generally subsides with continued therapy. If hypercalcaemia occurs, treat as appropriate; discontinue tamoxifen if severe. Monitor serum calcium closely in the first weeks of therapy for metastatic disease with bone involvement.
Drug Interactions
Tamoxifen is a prodrug requiring hepatic activation via CYP2D6 and CYP3A4. Drug interactions that alter the activity of these enzymes can significantly affect active metabolite levels and potentially reduce efficacy or increase toxicity. The CYP2D6 interaction with certain SSRIs is one of the most clinically important pharmacogenomic drug interactions in oncology.
Monitoring
- CBC with PlateletsPeriodically during therapy
RoutineThrombocytopenia (usually 50,000–100,000/mm3) may occur. Leukopenia, neutropenia, and pancytopenia also reported. Perform periodic CBCs (FDA PI Section 5.9). - Liver Function TestsPeriodically during therapy
RoutineFatty liver, cholestasis, hepatitis, and hepatic necrosis (some fatal) have been reported. Check LFTs at baseline and periodically thereafter (FDA PI Section 5.4, 5.9). - Gynaecological ExamAnnually during and after therapy
RoutineAnnual pelvic exam. Promptly evaluate any abnormal vaginal bleeding, discharge, or pelvic pain. Routine endometrial sampling/ultrasound in asymptomatic women is NOT recommended (FDA PI). - MammographyAnnually
RoutineAnnual mammography per breast cancer surveillance guidelines. Monthly breast self-examination. - Eye ExaminationBaseline; if visual symptoms
Trigger-basedCataracts (RR 1.13), cataract surgery (RR 1.62), retinal vein thrombosis, and corneal changes reported. Promptly evaluate any visual disturbance (FDA PI Section 5.8). - Lipid PanelPeriodically if preexisting hyperlipidaemia
Trigger-basedTamoxifen may increase triglycerides. Monitor in patients with preexisting hyperlipidaemia (FDA PI Section 5.9). May also improve total cholesterol via estrogenic effect. - VTE SymptomsEvery visit
RoutineScreen for leg pain/swelling, dyspnoea, chest pain at each visit. Discontinue tamoxifen before elective surgery requiring extended immobilisation; resume when fully ambulatory.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to tamoxifen or any component (angioedema, serious skin reactions reported)
- Pregnancy — Teratogenic; DES-like effects in offspring. Verify pregnancy status before starting; use non-hormonal contraception during and for 9 months after last dose.
- Concurrent warfarin or history of DVT/PE — when tamoxifen is being used for DCIS or breast cancer risk reduction (FDA PI Section 4). Not contraindicated for breast cancer treatment, but requires close INR monitoring.
Relative Contraindications (Specialist Input Recommended)
- History of thromboembolic events (when used for breast cancer treatment) — Carefully weigh risk-benefit; coadministration with chemotherapy further increases VTE risk.
- Strong CYP2D6 inhibitor co-therapy — May substantially reduce endoxifen levels and compromise tamoxifen efficacy. Switch antidepressant or consider alternative endocrine agent.
- Pre-existing endometrial pathology — Estrogenic effect on endometrium increases risk of further hyperplasia or malignancy in susceptible women.
Use with Caution
- CYP2D6 poor metabolisers — Genotyping not routinely recommended but may inform therapy decisions at some centres. Lower endoxifen levels are associated with this phenotype.
- Hepatic impairment — Tamoxifen is extensively hepatically metabolised; no specific dose adjustment but use with caution and monitor LFTs closely.
- Patients requiring immobilisation or planned surgery — Discontinue tamoxifen prior to elective surgery requiring extended bed rest; resume when ambulatory.
Serious and life-threatening events from the use of tamoxifen include uterine malignancies, stroke, and pulmonary embolism. Fatal cases of each type have occurred. NSABP P-1 trial rates per 1,000 women-years: endometrial adenocarcinoma 2.20 vs 0.71 placebo; uterine sarcoma 0.17 vs 0.04; stroke 1.43 vs 1.00; pulmonary embolism 0.75 vs 0.25. Discuss risks and benefits with women at high risk and with DCIS before initiating tamoxifen for risk reduction. For most patients already diagnosed with breast cancer, the benefits of tamoxifen outweigh its risks.
Patient Counselling
Purpose of Therapy
Tamoxifen works by blocking oestrogen from fuelling breast cancer cells, reducing the risk of the cancer coming back or developing in the first place. It is taken as a tablet once daily, usually for 5 to 10 years. Taking the medication consistently for the full prescribed duration is essential — studies show that women who take tamoxifen for the full course have significantly better outcomes than those who stop early.
How to Take
Take tamoxifen at roughly the same time each day, with or without food. If a dose is missed, take it as soon as remembered unless it is close to the next dose — do not double up. Store at room temperature away from moisture and light. Tamoxifen interacts with some common medications, including certain antidepressants — always inform all healthcare providers that you are taking tamoxifen.
Sources
- Soltamox (tamoxifen citrate) oral solution — Full Prescribing Information. Revised 09/2018. NDA 021807. FDA Label (2018)Primary source for dosing, boxed warning, adverse reactions, drug interactions, and monitoring recommendations. Contains the most current restructured FDA PI for tamoxifen citrate.
- Tamoxifen citrate tablets — DailyMed Prescribing Information. Multiple manufacturers. DailyMedRepresentative generic tamoxifen citrate tablet label with comprehensive clinical pharmacology and trial data.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388. doi:10.1093/jnci/90.18.1371NSABP P-1 trial (N=13,388). Demonstrated 49% reduction in invasive breast cancer with 5 years of tamoxifen 20 mg daily in high-risk women. Provides all boxed-warning incidence rates.
- Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1ATLAS trial. 10 years of adjuvant tamoxifen reduced breast cancer recurrence by 25% and mortality by ~30% vs 5 years, during years 10–14 of follow-up.
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467. doi:10.1016/S0140-6736(97)11423-4Landmark EBCTCG 1998 overview of 55 trials (36,689 women). Established that ~5 years of tamoxifen reduces recurrence by 47% and mortality by 26% in ER+ disease.
- Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: NSABP B-24. Lancet. 1999;353(9169):1993–2000. doi:10.1016/S0140-6736(99)05036-9NSABP B-24 trial. In DCIS patients after lumpectomy and radiation, tamoxifen reduced ipsilateral invasive breast cancer events (RR 0.57).
- Burstein HJ, Lacchetti C, Griggs JJ, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019;37(5):423–436. doi:10.1200/JCO.18.01160ASCO guideline recommending 5–10 years of adjuvant tamoxifen in premenopausal women with HR+ breast cancer, with sequential AI after menopause.
- Visvanathan K, Fabian CJ, Bantug E, et al. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2019;37(33):3152–3165. doi:10.1200/JCO.19.01472ASCO guideline on chemoprevention: recommends tamoxifen 20 mg daily for 5 years in women ≥35 years with 5-year Gail risk ≥1.67%. Discusses risk-benefit balance.
- Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, endoxifen plasma concentrations, and clinical outcomes in breast cancer patients treated with tamoxifen. Clin Pharmacol Ther. 2005;78(4):381–392. doi:10.1016/j.clpt.2005.06.005Key study demonstrating that CYP2D6 genotype determines endoxifen concentrations and that strong CYP2D6 inhibitors (e.g., paroxetine) markedly reduce endoxifen levels.
- Tamoxifen. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated 2025 Mar 28. NCBI BookshelfComprehensive pharmacology review covering mechanism, PK, adverse effects, interactions, and clinical indications for tamoxifen.
- Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49(8):2175–2183. PMID:2702659Foundational PK study characterising tamoxifen metabolite profiles including endoxifen and 4-OH-tamoxifen in plasma and tumour tissue.
- Helland T, Henne N, Bifulco E, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017;19(1):125. doi:10.1186/s13058-017-0916-4Demonstrates that higher serum endoxifen concentrations are associated with improved long-term outcomes, supporting the clinical relevance of CYP2D6-mediated metabolism.